Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alatrofloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 1/20 | 0.69 |
| ▸ | FLT4 | P35916 | 1/20 | 0.69 |
| ▸ | GSK3B | P49841 | 1/20 | 0.69 |
| ▸ | RARB | P10826 | 1/20 | 0.69 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | XBP1 | P17861 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.68 |
| ▸ | RELA | Q04206 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 6/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alatrofloxacin SCHEMBL140567 | 1.00 | EPHA2 (0.69) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL29493446 | 1.00 | EPHA2 (0.69) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL7618000 | 1.00 | EPHA2 (0.69) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL7101443 | 1.00 | EPHA2 (0.69) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL6848316 | 0.97 | EPHA2 (0.65) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL28214885 | 0.97 | EPHA2 (0.75) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL29389843 | 0.97 | LMNA (0.73) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL41134 | 0.97 | LMNA (0.73) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Alatrofloxacin SCHEMBL8186971 | 0.97 | LMNA (0.73) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL9735079 | 0.95 | EPHA2 (0.74) | EPHA2FLT4GSK3BRARBTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452124-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-10-08 | — | — | EP | claimed |
| EP-3452123-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-09-24 | — | — | EP | claimed |
| EP-3230500-B1 | METHODS OF ORIENTING MULTIFILAMENT YARN AND MONOFILAMENTS OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF | TEPHA INC (US) | 2025-06-18 | — | — | EP | claimed |
| EP-3678715-B1 | CALENDERED SURGICAL MESHES COMPRISING POLYHYDROXYALKANOATES | TEPHA INC (US) | 2024-10-30 | — | — | EP | claimed |
| EP-3802062-B1 | METHODS FOR 3D PRINTING OF POLY-4-HYDROXYBUTYRATE | TEPHA INC (US) | 2024-09-18 | — | — | EP | claimed |
| EP-3122757-B1 | CHARGED LINKERS AND THEIR USES FOR CONJUGATION | HANGZHOU DAC BIOTECH CO LTD (CN) | 2023-09-06 | — | — | EP | claimed |
| EP-3452122-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2023-03-22 | — | — | EP | claimed |
| US-5164402-A | Bactericides | PFIZER INC (US) | 1992-11-17 | — | — | US | claimed |
| WO-2025242720-A1 | METHOD FOR FLUORINATION OF A HALOPYRIDINE CATALYZED BY NANODIAMONDS | UNIVERSITE DE POITIERS (FR) | 2025-11-27 | — | — | WO | disclosed |
| US-20250325494-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | THEMEDIUM THERAPEUTICS CO., LTD. (CN) | 2025-10-23 | — | — | US | disclosed |
| US-20250188013-A1 | LIPID COMPOUND AND USE THEREOF | THEMEDIUM THERAPEUTICS CO., LTD. (CN) | 2025-06-12 | — | — | US | disclosed |
| WO-2025111413-A1 | TREATMENT FOR SKIN DISORDERS | Mycotechnology, Inc. (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-3903820-B1 | AN ANTI-CERAMIDE ANTIBODIES | SLOAN KETTERING INST CANCER RES (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4400491-A1 | NOVEL LIPIDS USED FOR NUCLEIC ACID DELIVERY AND LIPID NANOPARTICLE COMPOSITION | Themedium Therapeutics Co., Ltd (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20070196504-A1 | PHARMACEUTICAL COMPOSITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070196504-A1 | PHARMACEUTICAL COMPOSITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-0833837-B1 | PROCESS FOR PREPARING DERIVATIVES OF AZABICYCLO NAPHTHYRIDINE CARBOXYLIC ACID COMPRISING A DIPEPTIDE | PFIZER (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-1997008191-A1 | POLYMORPHS OF THE PRODRUG 6-N-(L-ALA-L-ALA)-TROVAFLOXACIN | PFIZER INC. (US) | 1997-03-06 | — | — | WO | disclosed |
| US-5391763-A | 3-aza-bicyclo[3.1.0]hexanes which are intermediates for anti-bacterial azabicyclo quinolone carboxylic acids | PFIZER INC. (US) | 1995-02-21 | — | — | US | disclosed |
| US-5164402-A | Bactericides | PFIZER INC (US) | 1992-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325494-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | FABP1, POLRMT, LIPC | EPHA2 1189/4885FLT4 1657/4885GSK3B 4848/4885 |
| US-20250188013-A1 | LIPID COMPOUND AND USE THEREOF | NPC1L1, CYP46A1, PCSK9 | EPHA2 1831/4885FLT4 3531/4885GSK3B 2688/4885 |
| US-20070196504-A1 | PHARMACEUTICAL COMPOSITION | CMA1, HRH2, ACLY | EPHA2 3640/4885FLT4 4103/4885GSK3B 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.